SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

Edwards Lifesciences might be a pioneer in the transcatheter aortic valve replacement market, but that doesn’t mean it’s smooth sailing in the space. The Irvine, CA-based company faces stiff ...

Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...

Edwards Lifesciences stock is supported by its growth outlook and the impact of clinical advances. See why investors should ...

Edwards Lifesciences stock surged Wednesday — and retook both its key moving averages — after beating fourth-quarter forecasts for its heart-valve replacements. Please watch the video at Investors.com ...

Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...